Creditsafe Realizes 234% ROI with BlackLine, Named Winner of 2025 Nucleus Research ROI Awards
LOS ANGELES, July 3, 2025 /CNW/ -- BlackLine, Inc. (Nasdaq: BL), the future-ready financial operations platform for the Office of the CFO, today announced that its customer Creditsafe, a global leader in business intelligence, has been named a winner of the 2025 Nucleus Research ROI Awards. The recognition highlights the measurable business impact of Creditsafe's BlackLine deployment, which achieved a 234% return on investment and a 12.4-month payback period.
Each year, Nucleus Research honors the top 10 technology deployments worldwide that achieve exceptional return on investment. Creditsafe was recognized for its success in automating collections and cash allocation processes with BlackLine, resulting in improved efficiency, increased visibility, and greater scalability across international operations.
" We're proud to see Creditsafe recognized among the top ROI-driven transformations of the year," said Andy Lilley, Managing Director, Global Invoice to Cash at BlackLine. "Their results are a testament to what's possible when forward-thinking finance teams embrace automation to drive measurable impact. BlackLine is here to make that success repeatable, scalable, and achievable for every customer."
Leveraging BlackLine's Invoice-to-Cash solution—including Collections Management and Cash Application —Creditsafe reduced operational costs, accelerated the cash lifecycle, and elevated their customer experience. The finance team can now support rapid global expansion without adding headcount.
This milestone reflects BlackLine's continued investment in innovation. The recent launch of BlackLine's modernized Cash Application user interface, now generally available, marks a significant evolution in BlackLine's Invoice-to-Cash journey – offering customers a more intelligent, streamlined, and intuitive experience.
"BlackLine streamlined our order-to-cash processes and freed our team to focus on value-added work," said Jason Braidwood, Global Head of Credit & Collections, Creditsafe. "I would advise any credit manager to adopt tools like BlackLine—it truly makes life easier."
This accolade reinforces BlackLine's continued leadership in delivering AI-enabled, outcome-focused solutions that empower finance, accounting, & credit teams to operate more strategically and efficiently. From accelerating time to value to enabling smarter decisions through unified data and automation, BlackLine is helping finance leaders transform their operations with confidence.
To learn more about how Creditsafe and other leading organizations are driving results with BlackLine, visit blackline.com/customers.
About BlackLine
BlackLine (Nasdaq: BL), the future-ready platform for the Office of the CFO, drives digital finance transformation by empowering organizations with accurate, efficient, and intelligent financial operations.
BlackLine's comprehensive platform addresses mission-critical processes, including record-to-report and invoice-to-cash, enabling unified and accurate data, streamlined and optimized processes, and real-time insight through visibility, automation, and AI. BlackLine's proven, collaborative approach ensures continuous transformation, delivering immediate impact and sustained value. With a proven track record of innovation, industry-leading R&D investment, and world-class security practices, more than 4,400 customers across multiple industries partner with BlackLine to lead their organizations into the future.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
19 minutes ago
- Globe and Mail
Femasys Revenue Jumps 85 Percent in Q2
Key Points Revenue surged 84.8% to $0.41 million (GAAP) in Q2 2025, far outpacing consensus estimates (GAAP) but still early-stage in scale. FemBloc gained its first-ever European approval; FemaSeed and FemVue secured new regulatory clearances and partnerships. Net loss (GAAP) narrowed slightly to $4.59 million, while cash reserves (GAAP) dropped to $3.22 million, bringing a near-term cash crunch. These 10 stocks could mint the next wave of millionaires › Femasys (NASDAQ:FEMY), a women's health medical technology firm developing permanent birth control and fertility solutions, released its second quarter 2025 results on August 8, 2025. The earnings report was marked by strong revenue growth to $0.41 million (GAAP)—an 84.8% jump in GAAP sales from the prior year period—driven by accelerating early-stage sales of FemaSeed intratubal insemination devices and FemVue diagnostic systems. This figure (GAAP revenue of $409,268) came in far above analyst estimates. The company posted a GAAP net loss of $4.59 million, a slight improvement from the $4.68 million GAAP net loss in Q2 2024. Diluted earnings per share (GAAP) was slightly better than analyst estimates at $(0.16). Despite clear commercial and regulatory progress, continued operating losses and a $3.22 million cash balance as of June 30, 2025 mean Femasys will need additional funding within the next quarter to sustain operations. Source: Analyst estimates for the quarter provided by FactSet. Femasys at a Glance and Business Focus Femasys designs and commercializes non-surgical products for women's reproductive health needs. Its main portfolio spans permanent birth control devices—most notably the FemBloc system—and fertility-related solutions like FemaSeed and FemVue. Recent company focus has been on winning new regulatory approvals, especially for FemBloc, and moving early-stage products from research and development into wider commercial sales. Key success factors for Femasys include clearing regulatory hurdles in each market, gaining adoption from clinics and patients, and forming the right distribution partnerships. Protecting its intellectual property is also essential given the specialized nature of its technology. Quarter Highlights: Financial and Product Progress Revenue (GAAP) climbed 84.8%, driven by sales of FemaSeed and FemVue. A roughly $400,000 order from Spain signals a pivotal step in international expansion efforts. Sales of FemaSeed intratubal insemination devices and FemVue diagnostic products—tools that facilitate fertility assessment—drove most of the top-line gain. Together, these products represent the company's early moves beyond the U.S. market. On the regulatory front, Femasys achieved a series of important clearances: FemBloc received its first European approval, marking the first global regulatory sign-off for a non-surgical permanent birth control option in the company's portfolio. FemaSeed and FemVue also gained approvals in Australia and New Zealand, expanding potential markets and laying groundwork for future sales. Ongoing enrollment in U.S. pivotal trials for FemBloc continues, which will be crucial for future coverage and adoption in the American healthcare market. The company expanded its reach through new partnerships. It announced a relationship with the Carolinas Fertility Institute, an eight-clinic network in the U.S, to offer FemaSeed to more patients. Distribution partnerships in Spain will support further commercialization of FemBloc. Femasys also shored up its patent portfolio, receiving notice of intent to grant new patents in Europe and the U.S. for FemBloc and FemaSeed, maintaining its lead in the emerging non-surgical device category. Financially, the net loss (GAAP) narrowed slightly to $4.59 million, reflecting both increased sales and a 28.4% drop in research and development expense as products transition to the commercial phase. However, cash burn remained high: the $3.22 million cash balance at June 30, 2025 gives the company only enough runway to operate into early fourth quarter, without additional funding. The company raised $4.5 million in new equity but continued operating losses have quickly reduced available resources. Inventory increased 71.8% year-to-date (as of June 30, 2025), showing strategic preparation for expected sales but also a concentration of capital in unsold goods. The share count rose from 23,355,926 as of December 31, 2024, to 32,575,407 as of June 30, 2025. Femasys does not currently pay a dividend. Looking Forward Femasys management did not provide specific revenue or earnings targets for the coming quarters or for fiscal 2025. Leadership emphasized that the next stages will focus on translating recent approvals and pilot orders into routine commercial adoption, particularly in the European Union and new Asia-Pacific markets, and continuing to build distribution and clinic partnerships. Given the current cash position as of June 30, 2025, the company expects its cash and cash equivalents will be sufficient to fund operations into the early fourth quarter of 2025. The expanding international footprint and product pipeline, along with progress on intellectual property protection, remain important areas for investors to monitor in the coming periods. FEMY does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,047%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
44 minutes ago
- Globe and Mail
After Skyrocketing Over 3,000% in 5 Years, Can MicroStrategy Stock Continue to Rise Higher?
Key Points MicroStrategy is the largest corporate holder of Bitcoin, and it's not even close. The company recently reported a mammoth profit due to gains on digital assets. Its Bitcoin-buying strategy has been working tremendously well, and other companies may follow suit. 10 stocks we like better than Strategy › Did you know that in five years, Bitcoin has risen more than 870% in value? It's a staggering return given that the S&P 500 is up just 91% over that same period. That's still a solid return, but it pales in comparison to Bitcoin. But what may be even more surprising is that a company that has simply been loading up on Bitcoins has been a far better buy than the cryptocurrency itself. MicroStrategy (NASDAQ: MSTR), which now goes by just "Strategy," has climbed a remarkable 3,000% in five years. It hasn't been experiencing huge sales growth or become a top artificial intelligence (AI) company. Instead, it has just been accumulating Bitcoins, and its enthusiasm for the cryptocurrency has made it a red-hot stock for retail investors to buy. However, with the company already accumulating such massive gains in a short time frame, is it due for a crash or at least a correction? Or could it still be a good buy today? More companies are following the same blueprint Strategy's remarkable returns over the years haven't gone unnoticed by other businesses. More companies are also eagerly investing in the top digital currency in the world as they try to appeal to retail investors. Social media stock Trump Media and Technology Group has recently announced it bought $2 billion in Bitcoin. The stock, largely a speculative play, is likely hoping a similar bullishness in crypto sends its valuation soaring. It's now the fifth-largest corporate holder of Bitcoin. Some other notable names that have accumulated significant amounts of Bitcoin include Block and Tesla. For Strategy, it is still far and away the leader, owning nearly 629,000 Bitcoins as of Aug. 4. The next-largest corporate position belongs to crypto mining company Mara Holdings, which has 50,000 Bitcoins. But the sheer success of Strategy's approach could entice other businesses to do the same and start accumulating significant holdings of Bitcoin as well. If the novelty of Strategy's stock wears off, that could result in less bullishness and excitement, potentially leading to more muted gains for it in the future. A disconnect with fundamentals could make the stock ripe for a sell-off Loading up on Bitcoins has enabled Strategy's valuation to grow to a market cap of $110 billion today. It's large enough to now be part of the Nasdaq 100 index, which is made up of the top non-financial stocks on the exchange. (Strategy is technically involved in providing companies with business intelligence and analytics software.) A quick look at some valuation metrics highlights just how egregiously priced the stock has become: Strategy trades at more than 200 times its revenue, and its estimated forward price-to-earnings multiple, which is based on analyst estimates, is over 1,200. In its most recent quarter, which ended on June 30, Strategy reported a monstrous net income of more than $10 billion despite only generating $115 million in revenue. The boost came, of course, from its position in digital assets. Strategy reported an unrealized gain of over $14 billion during the period, which was offset partly by a nearly $4 billion provision for income taxes. The business has benefited significantly from Bitcoin's rising valuation and the digital currency hitting record levels this year, but with such a large valuation and enormous volatility on its financials, it makes Strategy a highly speculative investment. Can Strategy's stock still be a good buy? If Bitcoin continues rallying and Strategy keeps on to its tally of Bitcoins, it wouldn't surprise me to see the crypto stock rise even higher in the future. The temptation may be to think that Bitcoin is destined to continue going higher, but that's by no means a sure thing. Without strong fundamentals to fall back on, Strategy is simply too volatile and risky of an investment to own. It has achieved significant gains in recent years, but that doesn't mean that the stock's future performance will mirror that. Unless you're a crypto enthusiast with a high tolerance for risk, you're likely better off avoiding Strategy's stock, as it could take you on a roller-coaster ride. Should you invest $1,000 in Strategy right now? Before you buy stock in Strategy, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Strategy wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bitcoin, Block, and Tesla. The Motley Fool recommends Nasdaq. The Motley Fool has a disclosure policy.
Globe and Mail
an hour ago
- Globe and Mail
3 No-Brainer Artificial Intelligence (AI) Stocks to Buy Now and Hold Forever
Key Points The biggest winners from the AI revolution will all have durable competitive advantages. Despite strong operating results, these stocks still look like great values amid the AI stock boom. With long-term potential gains from AI, you can buy them now and hold them forever. 10 stocks we like better than Amazon › Excitement around artificial intelligence (AI) and its potential impact on businesses has led to soaring stock prices for many of the biggest tech companies. Nvidia, for example, has seen its stock price grow more than tenfold since the release of ChatGPT in late 2022, now topping $4 trillion in market cap. Some investors may feel like they've missed the boat and they're too late to buy AI stocks at a good price. It's important to consider that today's AI winners might not be the biggest companies to benefit from advancements in artificial intelligence over the long run. Finding a company that's making excellent progress right now with sustainable long-term competitive advantages could end up being an even better stock to own when the dust settles. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » These three companies are all well positioned to benefit from the continued growth and advancement in artificial intelligence. Their stocks are all attractive at today's prices, too, which means you can buy them now and hold them forever. 1. Amazon Amazon (NASDAQ: AMZN) is home to the largest public cloud computing platform in the world, Amazon Web Services, or AWS. The segment generated $116.4 billion over the last 12 months, roughly 50% larger than its next-closest competitor, Microsoft 's Azure. Some have expressed concern about AWS for a few reasons. First, it was caught flat-footed as the generative AI opportunity was getting off the ground. That led it to cede market share to Microsoft and others who were earlier to invest in the space. However, it quickly course corrected, releasing its Bedrock platform, and it's seeing triple-digit growth in AI services. As such, it's been able to maintain most of its market share in a rapidly growing market (even though overall revenue growth has slowed to the high-teens). The second reason is that AWS saw a significant decline in operating margin in the second quarter. Management explained half of that decline was due to the timing of stock-based compensation. The rest is explained by Amazon's significant investments in capacity, as it notes the business remains capacity constrained. Over time, investors should see margin tick back up. It's worth noting AWS still commands higher margins than its smaller competitors. Meanwhile, the rest of Amazon looks strong. Its retail operations are seeing improved margins quarter after quarter, thanks in part to a strong advertising business. The international segment is notably on its way to becoming a meaningful contributor to operating income after years of investment. The stock fell following the release of its second-quarter earnings based on a disappointing outlook. But the long-term potential for Amazon, particularly in AWS, remains strong. The pullback in price looks like an opportunity for long-term investors to buy this AI leader. 2. Salesforce Salesforce (NYSE: CRM) provides a suite of software often found at the center of many enterprises' operations. The company has seen very good results with its growing set of cloud-based software solutions, but the standout recently has been its Data Cloud offering. Data Cloud provides a single platform to aggregate all of a company's data to create actionable insights from a single source. Data Cloud recurring revenue grew to $1 billion in Salesforce's most recent quarter, up 120% year over year. It's seeing strong attachment, with 60 of its top 100 deals including Data Cloud in the contract. And the most recent product built on top of Data Cloud, Agentforce, is seeing very strong adoption. Agentforce allows businesses to build AI agents that can execute tasks or provide customer service with minimal human intervention. The key to building successful AI agents is access to pertinent data, which is exactly what Data Cloud brings to the table. Management says it's made 8,000 deals with Agentforce since its launch last fall, representing $100 million in revenue. That makes it Salesforce's fastest-growing product ever. Considering Salesforce's software suite is entrenched in the operations of so many enterprises, it's in a prime position to benefit from growing spend on artificial intelligence, particularly through Data Cloud. It's unlikely to lose that position. In fact, its expanding suite of software tools only serves to increase the switching costs for a company. With shares trading for just 22 times forward earnings estimates, Salesforce looks like a great buy at today's price. 3. Meta Platforms Meta Platforms (NASDAQ: META) may be the biggest investor in artificial intelligence in the world. It's on track to spend between $66 billion and $72 billion on capital expenditures, and it's only building compute power for itself (unlike the other hyperscalers, who serve cloud customers). There's a good reason Meta is spending more than everyone else on artificial intelligence; it could be the biggest beneficiary of all generative AI has to offer. Signs of that are already coming through. In the second quarter, Meta's ad prices climbed 9% year over year and impressions grew 11%. CEO Mark Zuckerberg notes a significant portion of that improvement came from its AI-recommendation model. Additionally, time spent on Facebook and Instagram increased 5% and 6%, respectively, thanks to bigger AI models. But the future is bright, too. Meta's generative AI tools for ad creative are seeing strong adoption. Zuckerberg notes "a meaningful... [percentage] of our ad revenue now... [comes] from campaigns using one of our Generative AI features." Long term, Meta is working on an AI agent that can develop and test ad creatives autonomously. Meta's AI chatbot now boasts over 1 billion users, creating an additional channel for monetization over the long run. Meta only recently started putting ads in WhatsApp and Threads, which should provide additional ad revenue as advertising on Meta grows increasingly easier thanks to generative AI capabilities. Meta's seeing excellent financial results from the growing adoption of its advertising platform and increased engagement from its users. Revenue climbed 22% last quarter and operating income grew an impressive 38%. Meta's growing depreciation expense will likely weigh on earnings going forward as long as it continues to ramp up spending, but if it continues to produce top-line growth like last quarter, that's easily digestible. If you back out the depreciation expense using EBITDA, Meta shares trade for an attractive price with enterprise value around 16 times forward EBITDA estimates. Even on a more traditional forward P/E valuation, Meta shares look to be well worth the 27 times multiple you'll have to pay for the stock today. Should you invest $1,000 in Amazon right now? Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
